Drugs / TDaP-IPV vaccine
TDaP-IPV vaccine
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02589678 | Aug 2015 → May 2017 | — | Emory University | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT04300192 | Jan 2021 → Jan 2023 | diphtheria, poliomyelitis, tetanus | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 4 | NCT02771782 | Jan 2015 → Jul 2016 | pertussis | Radboud University Medical Center | Unknown | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TDaP-IPV vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02771782 ↗ |
| Known as | Adacel Quadra | “Group 1: Adacel Quadra vaccine” NCT04300192 ↗ |
| Known as | Adacel-Polio, Adacel Quadra | “Adacel®-Polio, Adacel Quadra®” NCT04300192 ↗ |
| Known as | Boostrix Polio | “Subjects are vaccinated with TDaP-IPV vaccine (Boostrix Polio) vaccine alone, 0,5ml intramuscular” NCT02771782 ↗ |
| Known as | tetanus-diphtheria-pertussis inactivated polio vaccine | “We randomized 75 healthy, female, adult volunteers to receive either BCG, followed by a booster dose of tetanus-diphtheria-pertussis inactivated polio vaccine (Tdap) 3 months...” PMID 30919883 ↗ Jan 2020 |
| Modality | Vaccine | “Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, combined with inactivated poliomyelitis vaccine” NCT02589678 ↗ |
| Route | Intramuscular | “will be administered intramuscularly” NCT02589678 ↗ |